Arcus Biosciences has presented early Phase II data on its TIGIT inhibitor, domvanalimab, but partner Gilead Sciences, Inc. is not yet committing to funding pivotal studies, even as an interim analyses, particularly of a triplet combination, give encouraging hints of efficacy.
TIGIT inhibitors are a promising new avenue in immuno-oncology therapy, and Arcus is in the race to bring the first...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?